Amino Acid PET to Assess the Efficacy of IDH Inhibitor Treatments for IDH Mutated Gliomas
TEP-IDH
Amino Acid PET Imaging to Assess the Efficacy of IDH Inhibitor Treatments for Patients With Refractory IDH Mutated Gliomas
1 other identifier
observational
22
1 country
1
Brief Summary
Amino acid PET imaging could represent a biomarker for the evaluation of IDH inhibitor treatments for patients with refractory IDH-mutated gliomas
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Jun 2025
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 4, 2025
CompletedFirst Posted
Study publicly available on registry
June 12, 2025
CompletedStudy Start
First participant enrolled
June 30, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
August 30, 2025
CompletedJune 12, 2025
June 1, 2025
1 day
June 4, 2025
June 4, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Compare the performance between amino acid PET and brain MRI to assess a treatment efficacy
Comparison between early therapeutic response according to RANO 1.0 and RANO 2.0 PET criteria and tumor progression at 6 months
one day
Secondary Outcomes (1)
Compare the performance between amino acid PET and brain MRI to assess a treatment efficacy for the identification of lesions
one day
Interventions
Patients received 18-fluoroDopa then a PET exam
Eligibility Criteria
Patients who underwent amino acid PET for early assessment of therapeutic response of IDH-mutated gliomas under anti-IDH treatment between February 2022 and November 2024
You may qualify if:
- Patients who underwent amino acid PET for early assessment of therapeutic response of IDH-mutated gliomas under anti-IDH treatment between February 2022 and November 2024
You may not qualify if:
- Individuals who have objected to the use of their data
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
CHRU of NANCY
Vandœuvre-lès-Nancy, 54511, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal investigator
Study Record Dates
First Submitted
June 4, 2025
First Posted
June 12, 2025
Study Start
June 30, 2025
Primary Completion
July 1, 2025
Study Completion
August 30, 2025
Last Updated
June 12, 2025
Record last verified: 2025-06